Laura Chico
Stock Analyst at Wedbush
(3.55)
# 909
Out of 4,996 analysts
222
Total ratings
44.08%
Success rate
7.28%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEPG PepGen | Maintains: Outperform | $7 → $9 | $5.07 | +77.51% | 11 | Sep 25, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $42 → $44 | $36.71 | +19.86% | 9 | Sep 12, 2025 | |
| TRML Tourmaline Bio | Downgrades: Neutral | $48 | $47.74 | +0.54% | 3 | Sep 9, 2025 | |
| JBIO Jade Biosciences | Maintains: Outperform | $17 → $18 | $8.48 | +112.26% | 3 | Aug 14, 2025 | |
| SLDB Solid Biosciences | Maintains: Outperform | $17 → $14 | $6.15 | +127.64% | 3 | Aug 13, 2025 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $16 → $22 | $24.14 | -8.86% | 7 | Aug 13, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $42 → $43 | $37.98 | +13.22% | 9 | Aug 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $30 → $32 | $25.30 | +26.48% | 12 | Aug 7, 2025 | |
| GOSS Gossamer Bio | Maintains: Outperform | $4 → $5 | $2.70 | +85.19% | 6 | Aug 6, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $13 → $14 | $5.54 | +152.71% | 14 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $137 → $141 | $142.00 | -0.70% | 10 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $34 | $29.08 | +16.92% | 13 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $27.00 | -37.04% | 1 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $7.63 | +135.91% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $15 | $5.10 | +194.41% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $130 | $126.04 | +3.14% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $121 | $137.37 | -11.92% | 18 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 | $24.17 | +11.73% | 7 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $3.95 | +1.27% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $30 | $13.95 | +115.05% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $26 | $28.20 | -7.80% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $28 | $52.02 | -46.17% | 7 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 | $16.05 | +167.91% | 10 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.73 | +73.41% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $7.30 | +283.56% | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $22.39 | +29.52% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $4.52 | +54.87% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $20.18 | +108.13% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.55 | +1,900.00% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $6.56 | -23.78% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $53.85 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $3.25 | +53.85% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $15.00 | +890.00% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $12.11 | +5,845.50% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $90.50 | +209.41% | 1 | Apr 21, 2017 |
PepGen
Sep 25, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $5.07
Upside: +77.51%
Dianthus Therapeutics
Sep 12, 2025
Maintains: Outperform
Price Target: $42 → $44
Current: $36.71
Upside: +19.86%
Tourmaline Bio
Sep 9, 2025
Downgrades: Neutral
Price Target: $48
Current: $47.74
Upside: +0.54%
Jade Biosciences
Aug 14, 2025
Maintains: Outperform
Price Target: $17 → $18
Current: $8.48
Upside: +112.26%
Solid Biosciences
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $6.15
Upside: +127.64%
Stoke Therapeutics
Aug 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $24.14
Upside: -8.86%
Xenon Pharmaceuticals
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $37.98
Upside: +13.22%
Travere Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $25.30
Upside: +26.48%
Gossamer Bio
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.70
Upside: +85.19%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $13 → $14
Current: $5.54
Upside: +152.71%
Jul 31, 2025
Maintains: Outperform
Price Target: $137 → $141
Current: $142.00
Upside: -0.70%
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $29.08
Upside: +16.92%
Jul 8, 2025
Initiates: Outperform
Price Target: $17
Current: $27.00
Upside: -37.04%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $7.63
Upside: +135.91%
Jun 24, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $5.10
Upside: +194.41%
Jun 18, 2025
Reiterates: Neutral
Price Target: $130
Current: $126.04
Upside: +3.14%
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $137.37
Upside: -11.92%
Jun 5, 2025
Reiterates: Outperform
Price Target: $27
Current: $24.17
Upside: +11.73%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $3.95
Upside: +1.27%
May 7, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $13.95
Upside: +115.05%
May 7, 2025
Maintains: Neutral
Price Target: $34 → $26
Current: $28.20
Upside: -7.80%
May 5, 2025
Maintains: Underperform
Price Target: $26 → $28
Current: $52.02
Upside: -46.17%
Apr 21, 2025
Maintains: Outperform
Price Target: $43
Current: $16.05
Upside: +167.91%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.73
Upside: +73.41%
Mar 12, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $7.30
Upside: +283.56%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $22.39
Upside: +29.52%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $4.52
Upside: +54.87%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $20.18
Upside: +108.13%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.55
Upside: +1,900.00%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $6.56
Upside: -23.78%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $53.85
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $3.25
Upside: +53.85%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $15.00
Upside: +890.00%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $12.11
Upside: +5,845.50%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $90.50
Upside: +209.41%